Troglitazione affects survival of human osteosarcoma cells

Enrico Lucarelli, Luca Sangiorgi, Veronica Maini, Giovanna Lattanzi, Sandra Marmiroli, Matteo Reggiani, Marina Mordenti, Giuliana Alessandra Gobbi, Francesca Scrimieri, Annarosa Zambon Bertoja, Piero Picci

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Activation of PPARγ, a transcription factor member of the family of peroxisome proliferator-activated receptors, induces apoptosis in several normal and tumor cell lines. In our study, we investigated whether treatment with troglitazone (TRO), a known PPARγ agonist, induced apoptosis in the human osteosarcoma (OS) cell lines G292, MG63, SAOS and U2OS that express PPARγ. In our experiments, TRO never induced apoptosis of OS cells; on the contrary, TRO increased cell number, based on MTT proliferation assay. Remarkably, the TRO-induced cell number increase depended on a decrease of apoptosis that naturally occurred in the culture and was not due to an increased cell proliferation rate. TRO also prevented staurosporin-induced apoptosis. The TRO-mediated survival effect correlated with the activation of Akt, a well-known mediator of survival stimuli. Our work describes a new function for TRO and indicates that the Akt survival pathway may be a mediator of TRO-induced increase of survival.

Original languageEnglish
Pages (from-to)344-351
Number of pages8
JournalInternational Journal of Cancer
Volume98
Issue number3
DOIs
Publication statusPublished - Mar 20 2002

Fingerprint

troglitazone
Osteosarcoma
Peroxisome Proliferator-Activated Receptors
Survival
Apoptosis
Cell Count
Tumor Cell Line

Keywords

  • Apoptosis
  • Nuclear receptors
  • Osteosarcoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Troglitazione affects survival of human osteosarcoma cells. / Lucarelli, Enrico; Sangiorgi, Luca; Maini, Veronica; Lattanzi, Giovanna; Marmiroli, Sandra; Reggiani, Matteo; Mordenti, Marina; Gobbi, Giuliana Alessandra; Scrimieri, Francesca; Bertoja, Annarosa Zambon; Picci, Piero.

In: International Journal of Cancer, Vol. 98, No. 3, 20.03.2002, p. 344-351.

Research output: Contribution to journalArticle

Lucarelli, E, Sangiorgi, L, Maini, V, Lattanzi, G, Marmiroli, S, Reggiani, M, Mordenti, M, Gobbi, GA, Scrimieri, F, Bertoja, AZ & Picci, P 2002, 'Troglitazione affects survival of human osteosarcoma cells', International Journal of Cancer, vol. 98, no. 3, pp. 344-351. https://doi.org/10.1002/ijc.10203
Lucarelli, Enrico ; Sangiorgi, Luca ; Maini, Veronica ; Lattanzi, Giovanna ; Marmiroli, Sandra ; Reggiani, Matteo ; Mordenti, Marina ; Gobbi, Giuliana Alessandra ; Scrimieri, Francesca ; Bertoja, Annarosa Zambon ; Picci, Piero. / Troglitazione affects survival of human osteosarcoma cells. In: International Journal of Cancer. 2002 ; Vol. 98, No. 3. pp. 344-351.
@article{a6444b2bf31348918d72d5ec3f270c93,
title = "Troglitazione affects survival of human osteosarcoma cells",
abstract = "Activation of PPARγ, a transcription factor member of the family of peroxisome proliferator-activated receptors, induces apoptosis in several normal and tumor cell lines. In our study, we investigated whether treatment with troglitazone (TRO), a known PPARγ agonist, induced apoptosis in the human osteosarcoma (OS) cell lines G292, MG63, SAOS and U2OS that express PPARγ. In our experiments, TRO never induced apoptosis of OS cells; on the contrary, TRO increased cell number, based on MTT proliferation assay. Remarkably, the TRO-induced cell number increase depended on a decrease of apoptosis that naturally occurred in the culture and was not due to an increased cell proliferation rate. TRO also prevented staurosporin-induced apoptosis. The TRO-mediated survival effect correlated with the activation of Akt, a well-known mediator of survival stimuli. Our work describes a new function for TRO and indicates that the Akt survival pathway may be a mediator of TRO-induced increase of survival.",
keywords = "Apoptosis, Nuclear receptors, Osteosarcoma, Survival",
author = "Enrico Lucarelli and Luca Sangiorgi and Veronica Maini and Giovanna Lattanzi and Sandra Marmiroli and Matteo Reggiani and Marina Mordenti and Gobbi, {Giuliana Alessandra} and Francesca Scrimieri and Bertoja, {Annarosa Zambon} and Piero Picci",
year = "2002",
month = "3",
day = "20",
doi = "10.1002/ijc.10203",
language = "English",
volume = "98",
pages = "344--351",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Troglitazione affects survival of human osteosarcoma cells

AU - Lucarelli, Enrico

AU - Sangiorgi, Luca

AU - Maini, Veronica

AU - Lattanzi, Giovanna

AU - Marmiroli, Sandra

AU - Reggiani, Matteo

AU - Mordenti, Marina

AU - Gobbi, Giuliana Alessandra

AU - Scrimieri, Francesca

AU - Bertoja, Annarosa Zambon

AU - Picci, Piero

PY - 2002/3/20

Y1 - 2002/3/20

N2 - Activation of PPARγ, a transcription factor member of the family of peroxisome proliferator-activated receptors, induces apoptosis in several normal and tumor cell lines. In our study, we investigated whether treatment with troglitazone (TRO), a known PPARγ agonist, induced apoptosis in the human osteosarcoma (OS) cell lines G292, MG63, SAOS and U2OS that express PPARγ. In our experiments, TRO never induced apoptosis of OS cells; on the contrary, TRO increased cell number, based on MTT proliferation assay. Remarkably, the TRO-induced cell number increase depended on a decrease of apoptosis that naturally occurred in the culture and was not due to an increased cell proliferation rate. TRO also prevented staurosporin-induced apoptosis. The TRO-mediated survival effect correlated with the activation of Akt, a well-known mediator of survival stimuli. Our work describes a new function for TRO and indicates that the Akt survival pathway may be a mediator of TRO-induced increase of survival.

AB - Activation of PPARγ, a transcription factor member of the family of peroxisome proliferator-activated receptors, induces apoptosis in several normal and tumor cell lines. In our study, we investigated whether treatment with troglitazone (TRO), a known PPARγ agonist, induced apoptosis in the human osteosarcoma (OS) cell lines G292, MG63, SAOS and U2OS that express PPARγ. In our experiments, TRO never induced apoptosis of OS cells; on the contrary, TRO increased cell number, based on MTT proliferation assay. Remarkably, the TRO-induced cell number increase depended on a decrease of apoptosis that naturally occurred in the culture and was not due to an increased cell proliferation rate. TRO also prevented staurosporin-induced apoptosis. The TRO-mediated survival effect correlated with the activation of Akt, a well-known mediator of survival stimuli. Our work describes a new function for TRO and indicates that the Akt survival pathway may be a mediator of TRO-induced increase of survival.

KW - Apoptosis

KW - Nuclear receptors

KW - Osteosarcoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0037139422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037139422&partnerID=8YFLogxK

U2 - 10.1002/ijc.10203

DO - 10.1002/ijc.10203

M3 - Article

VL - 98

SP - 344

EP - 351

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -